We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-12.1%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.42B
AUM Growth
-$747M
Cap. Flow
-$166M
Cap. Flow %
-6.88%
Top 10 Hldgs %
25.87%
Holding
144
New
14
Increased
42
Reduced
23
Closed
13

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$54.6M
2
APLT
Applied Therapeutics
APLT
+$33.4M
3
CNC icon
Centene
CNC
+$31.6M
4
BPMC
Blueprint Medicines
BPMC
+$22.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$19.1M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$106M
2
UNH icon
UnitedHealth
UNH
+$80.1M
3
JNJ icon
Johnson & Johnson
JNJ
+$64.2M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$35.2M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$29M

Sector Composition

Rank Sector Weight
1 Healthcare 95.03%
2 Consumer Staples 1.05%
3 Consumer Discretionary 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
26
argenx
ARGX
$54.2B
$32.6M 1.35%
247,500
– –
BMRN icon
27
BioMarin Pharmaceuticals
BMRN
$13.3B
$32.1M 1.33%
380,000
+42,500
+13% +$3.66M
CHRS icon
28
Coherus Oncology
CHRS
$192M
$31.6M 1.31%
1,950,000
– –
EPZM
29
DELISTED
Epizyme, Inc
EPZM
$30.3M 1.25%
1,955,000
-95,000
-5% -$2.04M
IDXX icon
30
Idexx Laboratories
IDXX
$46.9B
$30.3M 1.25%
125,000
+4,800
+4% +$1.25M
PCRX icon
31
Pacira BioSciences
PCRX
$974M
$30.2M 1.25%
900,000
-250,000
-22% -$10.4M
VRTX icon
32
Vertex Pharmaceuticals
VRTX
$133B
$29.7M 1.23%
125,000
-78,000
-38% -$17.9M
SGEN
33
DELISTED
Seagen Inc. Common Stock
SGEN
$27.9M 1.15%
242,000
– –
APLT
34
DELISTED
Applied Therapeutics
APLT
$27.6M 1.14%
845,700
+825,385
+4,063% +$33.4M
ARDX icon
35
Ardelyx
ARDX
$997M
$27.6M 1.14%
4,850,000
– –
ONC
36
BeOne Medicines Ltd
ONC
$40.6B
$26.4M 1.09%
214,800
– –
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$26.3M 1.09%
341,500
+41,500
+14% +$3.72M
AMGN icon
38
Amgen
AMGN
$226B
$25.5M 1.06%
126,000
– –
FRPT icon
39
Freshpet
FRPT
$3.26B
$25.4M 1.05%
397,500
+42,250
+12% +$2.71M
CI icon
40
Cigna
CI
$73.6B
$25M 1.03%
141,000
+66,000
+88% +$12.8M
EXAS
41
DELISTED
Exact Sciences
EXAS
$24.6M 1.02%
424,000
+4,000
+1% +$325K
ASND icon
42
Ascendis Pharma A/S
ASND
$16.8B
$24M 0.99%
213,500
– –
ASMB icon
43
Assembly Biosciences
ASMB
$530M
$22.2M 0.92%
125,000
– –
ALGN icon
44
Align Technology
ALGN
$12.5B
$22.2M 0.92%
127,500
+16,600
+15% +$3.98M
COLL icon
45
Collegium Pharmaceutical
COLL
$882M
$19.2M 0.79%
1,175,000
-400,000
-25% -$8.26M
QURE icon
46
uniQure
QURE
$3.2B
$19M 0.78%
400,000
– –
AMRN
47
Amarin Corp
AMRN
$298M
$18.6M 0.77%
232,500
– –
INCY icon
48
Incyte
INCY
$24.6B
$18.3M 0.76%
250,000
– –
MIRM icon
49
Mirum Pharmaceuticals
MIRM
$6.02B
$17.4M 0.72%
1,243,000
-2,000
-0.2% -$32.8K
APRE icon
50
Aprea Therapeutics
APRE
$7.98M
$17.4M 0.72%
25,000
-11,200
-31% -$8.22M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Rock Springs Capital Management held 144 positions worth $2.42B, down 24% from $3.16B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management withdrew a net $166M in Q1 2020, closing 13 positions and reducing 23 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

Against the trend, Rock Springs Capital Management opened a new position in Biogen worth $56.9M.

  • Rock Springs Capital Management's largest Q1 2020 buy was Biogen: 180,000 shares worth $56.9M.
  • Rock Springs Capital Management added most to Applied Therapeutics in Q1 2020, an estimated $33.4M increase.
  • Rock Springs Capital Management's biggest Q1 2020 reduction was UnitedHealth, cutting an estimated $80.1M.
  • Rock Springs Capital Management fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $106M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $2.42B portfolio in Q1 2020.
  • Rock Springs Capital Management opened 14 new positions and closed 13 in Q1 2020.
  • Rock Springs Capital Management's portfolio value fell 24% quarter-over-quarter to $2.42B.

Based on Rock Springs Capital Management's 13F filing for Q1 2020, filed 15 May 2020.